Rocrock Bio Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2021

Location

Suzhou Jiangsu China

Primary Industry

Biotechnology

About

Based in Suzhou, China, and founded in 2019, Rocrock Bio operates as a provider of engineered macrophage technology, focusing on the development and clinical application of macrophage drugs for the treatment of solid tumors. The branches have been set up in Shenzhen and Berlin. The founder, Dr. Xiushan Yin, is a senior researcher at Karolinska Medical School, in Sweden. The company has completed the declaration and approval of nearly 40 patents and established partnerships with SYPM, Peking Union Medical College Hospital, and so on. It won first place in the Dongwu Science and Technology Innovation and Entrepreneurship Competition in August 2022 and closed a pre-series A funding in February 2024. Rocrock Bio's core platforms include the "24H-CAR" technology platform for chimeric antigen receptor macrophage (CAR-M) preparation, the "ADM-CAR" enhanced synthesis platform based on iterative screening of macrophage activation structural domains, the "Del-M" macromolecule delivery platform using macrophages as carriers, and the "M-DB" subtype database and target database platform. The platforms and drugs can be used to treat breast cancer, lung cancer, liver cancer, and other rare diseases. The company will use the pre-series A funds for the IND application of clinical pipeline RR-M01 and the construction of the Qingdao Kunshi Biological Delivery Carrier Production Base.

Current Investors

ASB Ventures, Shenzhen Liman Caixiang Technology, Qingdao Guozhu Asset Management

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development

Website

www.rocrockbio.com

Verticals

HealthTech

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.